NCT05835752View on ClinicalTrials.gov

The Safety, Tolerability and Pharmacokinetic Study of RAY1225

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

May 18, 2023

Primary Completion Date

March 1, 2024

Study Completion Date

March 23, 2024

Conditions
ObeseHealthy
Interventions
DRUG

RAY1225

Administered SC

DRUG

Placebo

Administered SC

DRUG

RAY1225

Administered SC

DRUG

Placebo

Administered SC

DRUG

RAY1225

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (1)

Unknown

Nanfang Hospital,South Medical Hospital, Guangzhou

All Listed Sponsors
lead

Guangdong Raynovent Biotech Co., Ltd

INDUSTRY

NCT05835752 - The Safety, Tolerability and Pharmacokinetic Study of RAY1225 | Biotech Hunter | Biotech Hunter